Altachem's Bionex validated as a hand gel disinfectant

- Product effective at unusually low alcohol concentrations - 

Trading Symbol: AAF:TSX Venture Exchange

EDMONTON, Aug. 22 /CNW/ - Altachem Pharma Ltd. ("Altachem") has received
testing results from the Shanghai Centre for Disease Control and Prevention in
China (Shanghai Academy of Preventative Medicine) which validates the use of
the Bionex formulation submitted as a hand gel disinfectant for medical and
commercial applications in China. This is the second series of successful
tests for Bionex and follows the earlier approval of Bionex as a Hard Surface
disinfectant, received in December, 2004. The results will allow Altachem to
file an application with the Chinese Ministry of Health for product approval.
Bionex Hand Gel can be used for the disinfection of hands and forearms of
medical staff before surgery or other aseptic procedures and for general use
as a waterless hand and skin disinfectant for infection control.
"This is further validation of the utility of Bionex and should add to
the value of the product as we seek partners for its further development,"
remarked Dr. David Cox, President and CEO, "Although Altachem is now focused
mainly on its anti-cancer programs, it is a significant bonus for us to
receive further evidence of the considerable potential of the Bionex range of
products".
The tests performed by the Shanghai Centre for Disease Control and
Prevention evaluated two formulations of the Bionex Hand Gel, containing 60%
and 40% alcohol respectively. Both formulations passed all of the tests
required by the Chinese National Technical Standards for Disinfection. The 40%
formulation represents one of the lowest alcohol concentrations in hand gels.
This is important because it minimizes the skin-drying effect of higher
alcohol content hand gels as well as reducing manufacturing costs.

About Altachem Pharma Ltd

The Corporation is a publicly traded (TSX Venture Exchange: AAF),   
Alberta-based pharmaceutical company committed to the development and
commercialization of new pharmaceutical products. It is developing a series of
products for the treatment of cancer and other proliferative diseases based on
its SonoLight and CDK platforms. It also has a profitable product in      
Accu-MAb(TM), a monoclonal-based diagnostic kit for whooping cough.

Except for historical information, this press release may contain   
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."

%SEDAR: 00008400E